Price Chart

Profile

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.
URL https://www.biogen.com
Investor Relations URL https://investors.biogen.com
HQ State/Province Massachusetts
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Mid Cap/Blend
Next Earnings Release Oct. 25, 2023 (est.)
Last Earnings Release Jul. 25, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.
URL https://www.biogen.com
Investor Relations URL https://investors.biogen.com
HQ State/Province Massachusetts
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Mid Cap/Blend
Next Earnings Release Oct. 25, 2023 (est.)
Last Earnings Release Jul. 25, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A